| Literature DB >> 24596613 |
Abstract
Tuberculosis is the chronic consumptive disease and currently the world's leading cause of death. Tuberculous spondylitis is a less common yet the most dangerous form of skeletal tuberculosis. The recent re-emergence of Mycobacterium tuberculosis (M. tuberculosis) hints at a possible resurgence of tuberculosis in the coming years. This article discusses the clinical manifestations, diagnosis and treatment of tuberculous spondylitis, and updates material that the author has previously published on the subject. Treatment should be individualized according to different indications which is essential to recovery. A treatment model is suggested on the basis of the author's vast personal experiences.Entities:
Keywords: Mycobacterium tuberculosis; Tuberculous spondylitis
Year: 2014 PMID: 24596613 PMCID: PMC3939378 DOI: 10.4184/asj.2014.8.1.97
Source DB: PubMed Journal: Asian Spine J ISSN: 1976-1902
Fig. 1Causes of reactivation of latent tuberculosis and management. HIV, human immunodeficiency virus; AIDs, acquired immunodeficiency syndrome; TNF, tumour necrosis factor tumour necrosis factor; TB, tuberculosis.
First and second line antituberculous agents
MAC, Mycobacterium avium complex.
Proposed chemotherapy formula for the drug-resistant M. tuberculosis
INH, isoniazid; SM, streptomycin; PZA, pyrazinamide; RMP, rifampin; EMB, ethambutol; AMK, amikacin; OFL, ofloxacin; CIP, ciprofloxacin; Pyr, pyronins.
Advantages and disadvantages of chemotherapy alone
Accepted antituberculous regimens
H, INH (isoniazid); R, rifampin; Z, pyrazinamide; E, ethambutol; Pa, PAS (para-aminosalicyic acid); S, streptomycin; AIF, anterior interbody fusion.
Advantages of surgical treatment